医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

Newly Diagnosed FLT3-ITD Positive

VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML

VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: AML Newly Diagnosed FLT3-ITD Positive VANFLYTA

2023年11月09日

VANFLYTA® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML

VANFLYTA® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: AML Newly Diagnosed FLT3-ITD Positive VANFLYTA

2023年08月09日

VANFLYTA® First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML

VANFLYTA® First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬遺伝学　 TimeLine: AML Newly Diagnosed FLT3-ITD Positive VANFLYTA

2023年07月21日

Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA

Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: AML Extended by FDA Newly Diagnosed FLT3-ITD Positive Quizartinib NDA Review for Patients with

2023年04月21日

Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed FLT3-ITD Positive AML

Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed FLT3-ITD Positive AML

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: AML Newly Diagnosed FLT3-ITD Positive

2021年11月19日